Can This Vaccine Prevent Ebola Outbreak?

Outbreaks of Ebola spreads and becomes a threat, particularly in the African continent. A number of medications and vaccines are being designed to address this one epidemic. Ebola attacks humans, monkeys, chimpanzees, gorillas, and other primates. The virus was first discovered in rural areas of Congo, Africa and immediately threatened the life of the sufferer.
Transmitted through bats as an intermediary, Ebola symptoms occur within 14-21 days. After the infection, the patient will experience high fever, headache, sore throat, joint pain, diarrhea, vomiting, until abdominal cramps. After a symptom, a further sign of bleeding occurs in various places (eyes, ears, nose, or bleeding in the internal organs), seizures, decreased awareness, and shock.

Recently, an Ebola vaccine is being tested to help control the outbreaks that specifically target the Congolese community. Will the Ebola vaccine be successful? Can people be saved with this one drug?

Trial of Ebola vaccine

Reporting from CNN, WHO is testing the dose of ebola vaccine against a number of people in Congo. There are more than 5,000 doses of experimental vaccine in Kinshasa as the state capital. The local government expects there to be about 4,000 additional doses.

"Most of the Ebola viruses could have infected healthy bodies, so the vaccine is arguably the first time it's efficacious to control the Ebola outbreak," said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAD) in the United States.

The vaccine, called rVSV-ZEBOV, should be stored in temperatures of minus 60 to minus 80 degrees Celsius. He is believed to be able to survive for two weeks on the temperature cooler.

Storage of experimental vaccine in a cooler in Mbandaka, one of the cities in Congo, is in preparation. The vaccine is designed to deal with several types of Ebola viruses namely Zaire, and Bundibugyo as one of the most common types of ebola virus .

The experimental vaccine works by inducing a body that can later protect against exposure to Ebola virus. Representing his institution, Fauci admits that the trial is still being applied for the validity of the vaccine in the future.

"Initially, this experimental vaccine proved to have efficacy when used in ring vaccinations in Guinea. However, trials that take place in Sierra Leone and Liberia are just to prove safety and ascertain whether it induces an immune response in the body, "he said.

A number of vaccines have been tested some time before. Even so, no one has been able to really cope with the spread of Ebola. Thus, an experimental vaccine called rVSV-ZEBOV is so desirable in coping with this deadly epidemic.

The world of medical fight against Ebola

According to dr. Anita Amalia Sari, the Ebola virus can also be transmitted by direct contact (through the wounded skin or mucous membranes) with the blood, organs and body fluids of an infected person. It can also be through contact with contaminated environments.

Men infected with ebola can still pass the virus through semen (semen) up to 7 days after healing. While the incubation period) ranges from 2 to 21 days.

"The prevention of not getting an Ebola virus is to avoid contact with infected blood and body fluids or with objects or tools contaminated with body fluids such as syringes. Health workers or people who handle and are close to Ebola patients are required to wear self-protection equipment, "he said.

The handling of the Ebola outbreak is now being pursued with this rVSV-ZEBOV vaccine. The results of the trial and the effectiveness of the experimental vaccine in overcoming Ebola will be announced shortly in the near future.

Iklan Atas Artikel

Iklan Tengah Artikel 1

Your link is here:

Iklan Tengah Artikel 2

Iklan Bawah Artikel